- Home
- SLNO vs FHI Comparison
SLNO vs FHI Comparison
Compare SLNO & FHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNO
- FHI
- Stock Information
- Founded
- SLNO 1999
- FHI 1955
- Country
- SLNO United States
- FHI United States
- Employees
- SLNO N/A
- FHI N/A
- Industry
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- FHI Investment Managers
- Sector
- SLNO Health Care
- FHI Finance
- Exchange
- SLNO Nasdaq
- FHI Nasdaq
- Market Cap
- SLNO 3.7B
- FHI 4.0B
- IPO Year
- SLNO 2014
- FHI N/A
- Fundamental
- Price
- SLNO $46.98
- FHI $49.49
- Analyst Decision
- SLNO Strong Buy
- FHI Buy
- Analyst Count
- SLNO 9
- FHI 7
- Target Price
- SLNO $114.89
- FHI $49.00
- AVG Volume (30 Days)
- SLNO 2.2M
- FHI 567.8K
- Earning Date
- SLNO 11-04-2025
- FHI 10-30-2025
- Dividend Yield
- SLNO N/A
- FHI 2.75%
- EPS Growth
- SLNO N/A
- FHI 50.93
- EPS
- SLNO N/A
- FHI 4.77
- Revenue
- SLNO $98,675,000.00
- FHI $1,742,513,000.00
- Revenue This Year
- SLNO N/A
- FHI $8.76
- Revenue Next Year
- SLNO $181.30
- FHI $5.75
- P/E Ratio
- SLNO N/A
- FHI $10.36
- Revenue Growth
- SLNO N/A
- FHI 8.98
- 52 Week Low
- SLNO $41.50
- FHI $35.05
- 52 Week High
- SLNO $90.32
- FHI $54.42
- Technical
- Relative Strength Index (RSI)
- SLNO 31.94
- FHI 45.48
- Support Level
- SLNO $66.12
- FHI $46.66
- Resistance Level
- SLNO $69.99
- FHI $50.48
- Average True Range (ATR)
- SLNO 3.71
- FHI 1.25
- MACD
- SLNO -2.47
- FHI 0.09
- Stochastic Oscillator
- SLNO 18.57
- FHI 53.32
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
About FHI Federated Hermes Inc.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $843.7 billion in managed assets at the end of June 2025, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (2%), and money market (75%) funds. The firm's cash-management operations are expected to generate around 52% of Federated's revenue this year, compared with 29%, 11%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (67% of AUM), institutional investors (26%), and international clients (7%).